Concepedia

CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study

Johan Vansteenkiste, Thanyanan Reungwetwattana, Kazuhiko Nakagawa, B.C. Cho, M.A. Cobo Dols, E.K. Cho, A. Bertolini, Sabine Bohnet, C. Zhou, K.H. Lee,

Annals of Oncology · 2017 · 33 citations · 0 references

DOI

Concepts